The appropriateness and type of chemotherapy or drug therapy will be determined by the multidisciplinary team. A number of patients may benefit from chemotherapy or drug therapy:

• before surgery (interval debulking) in suspected stage III or IV ovarian cancer, to reduce the volume of the tumour before surgery
• after surgery in all stages except where the cancer was clearly confined to one or both ovaries and considered low risk for recurring
• after surgery for stage III ovarian cancer where no residual disease has been left. Some patients may be considered for a combination of intraperitoneal and intravenous chemotherapy.

In selected cases, chemotherapy may be considered as part of primary treatment.

Intraperitoneal chemotherapy should be provided in a centre with appropriate expertise, and potential toxicities should be fully explained to the patient and her family (Cancer Australia 2014).

Timeframes for starting treatment

• Neoadjuvant chemotherapy should begin within two weeks of the MDM.
• Adjuvant chemotherapy should begin within four weeks of surgery.

Training and experience required of the appropriate specialists

Medical oncologists must have training and experience of this standard:

• Fellow of the Royal Australian College of Physicians (or equivalent)
• adequate training and experience that enables institutional credentialing and agreed scope of practice within this area (ACSQHC 2015)
• appropriate expertise if providing IP chemotherapy.

Cancer nurses should have accredited training in these areas:

• anti-cancer treatment administration
• specialised nursing care for patients undergoing cancer treatments, including side effects and symptom management
• the handling and disposal of cytotoxic waste (ACSQHC 2020).

Systemic therapy should be prepared by a pharmacist whose background includes this experience:

• adequate training in systemic therapy medication, including dosing calculations according to protocols, formulations and/or preparation.

In a setting where no medical oncologist is locally available (e.g. regional or remote areas), some components of less complex therapies may be delivered by a general practitioner or nurse with training and experience that enables credentialing and agreed scope of practice within this area. This should be in accordance with a detailed treatment plan or agreed protocol, and with communication as agreed with the medical oncologist or as clinically required.

The training and experience of the appropriate specialist should be documented.

Health service characteristics

To provide safe and quality care for patients having systemic therapy, health services should have these features:

• a clearly defined path to emergency care and advice after hours
• access to diagnostic pathology including basic haematology and biochemistry, and imaging
• cytotoxic drugs prepared in a pharmacy with appropriate facilities
• occupational health and safety guidelines regarding handling of cytotoxic drugs, including preparation, waste procedures and spill kits (eviQ 2019b)
• guidelines and protocols to deliver treatment safely (including dealing with extravasation of drugs)
• coordination for combined therapy with radiation therapy, especially where facilities are not co-located
• appropriate molecular pathology access